Revision as of 19:32, 11 September 2018 (view source) MariePeras (Talk | contribs) ← Older edit		Revision as of 19:33, 11 September 2018 (view source) MariePeras (Talk | contribs) Newer edit →
Line 4:		Line 4:
−	<--!<div class="column full_size judges-will-not-evaluate">	+	<!-- <div class="column full_size judges-will-not-evaluate">
	<h3>★  ALERT! </h3>		<h3>★  ALERT! </h3>
	<p>This page is used by the judges to evaluate your team for the <a href="https://2018.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2018.igem.org/Judging/Awards"> award listed below</a>. </p>		<p>This page is used by the judges to evaluate your team for the <a href="https://2018.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2018.igem.org/Judging/Awards"> award listed below</a>. </p>

---

Revision as of 19:33, 11 September 2018

Proof of concept : analyse of spermtozoa motility

Introduction

Antimicrobial peptides (AMPs) have a great affinity for spermatozoa membranes. They are composed of anionic phospholipids such as phosphatidylglycerol and phosphatidylserine in the plasma membrane. Therefore AMP have to ability to inhibit motility of spermatozoa and prevent the fertilization. Antisperm antibodies are antibodies that can fix on specific parts of spermatozoa (YLP12 antigen) and inhibit their motility. The exact mechanism for this motility inhibition is not known yet. We quantified the action of the AMPs and antibodies on the motility of spermatozoa. This is our proof of concept to test the anticonceptional efficiency of the molecules produced by our bacteria.